A venture capital firm headquartered in the US invests in early-stage opportunities to translate key insights in human biology into viable therapeutics. The firm believes that no target is “undruggable” – rather, it is currently “undone”. The firm is open to sharing expertise in developing comprehensive chemical equity strategies and their “whatever it takes” mindset to identify high-quality candidates for clinical proof-of-concept. The firm makes investments ranging from $1-10M in Series A companies focusing in the U.S. and Europe.
The firm focuses mostly on therapeutics in pre-clinical and clinical stages and is drawn to the compelling targets which have emerged from population-wide genetic association studies, where human loss-of-function mutations point to an inhibitor strategy, and gain-of-function mutations provide a gene dose-response. The firm is opportunistic in terms of subsector and indication and is willing to consider companies targeting orphan indications.
The firm looks to act as a lead investor in seed round investments and can participate as either lead or co-investor in series A investments. The firm s looking for companies with skilled and experienced management teams. The firm prefers to support companies that own exclusive IP protection with renowned universities or research institutions. The firm also prefers to work with companies that have a technical expert and experienced in clinical trials.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment